242 related articles for article (PubMed ID: 30765472)
1. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
Reda G; Cassin R; Dovrtelova G; Matteo C; Giannotta J; D'Incalci M; Cortelezzi A; Zucchetti M
Haematologica; 2019 May; 104(5):e222-e223. PubMed ID: 30765472
[No Abstract] [Full Text] [Related]
2. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
[No Abstract] [Full Text] [Related]
3. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
5. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
6. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
7. How I manage CLL with venetoclax-based treatments.
Wierda WG; Tambaro FP
Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
9. Pairing obinutuzumab with venetoclax in relapsed CLL.
Rogers KA; Thompson PA
Leuk Lymphoma; 2024 May; 65(5):543-545. PubMed ID: 38497550
[No Abstract] [Full Text] [Related]
10. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
13. Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia.
Soumerai JD; Takvorian RW; Sohani AR; Abramson JS; Ferry JA
Lancet Haematol; 2022 Oct; 9(10):e796. PubMed ID: 36174642
[No Abstract] [Full Text] [Related]
14. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
15. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
Zou HS; Yi SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
[No Abstract] [Full Text] [Related]
16. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
18. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
19. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Roberts AW; Ma S; Kipps TJ; Coutre SE; Davids MS; Eichhorst B; Hallek M; Byrd JC; Humphrey K; Zhou L; Chyla B; Nielsen J; Potluri J; Kim SY; Verdugo M; Stilgenbauer S; Wierda WG; Seymour JF
Blood; 2019 Jul; 134(2):111-122. PubMed ID: 31023700
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
[No Abstract] [Full Text] [Related]
[Next] [New Search]